Möchten Sie immer auf dem neuesten Stand bleiben?

NorthStrive Biosciences Files Two New U.S. Patent Applications Targeting Muscle Preservation in GLP-1 and Next-Generation Obesity Treatment Markets

Austin, TX, USA, June 17, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “GLP-1 Receptor Agonist Market Size, Trends and Insights By Product Type...

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- TheDoseReport.com announces the release of its comprehensive Medvi Review, focusing on telehealth GLP-1 programs for weight management. Considering GLP-1...

Novo Nordisk's Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity for adults

MTRX31 led to a highly significant decrease in fat mass after two-months chronic dosing in a preclinical diet-induced obesity mouse model performed at thermoneutrality Weight loss and reduction of fat...

Company announcement No. 21 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel...

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Press release – No. 13 / 2026  New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small...